Cantargia publishes year-end report for 2016
Cantargia AB’s (”Cantargia”) year-end report for the year 2016 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the fourth quarter Preclinical studies using CAN04 in non-small cell lung cancer models were presented at the international Protein & Antibody Engineering Summit and results generated using Cantargia’s antibodies in studies in preclinical models of chronic myeloid leukemia were presented at the American Society of Hematology. Warrants of series TO 2 and series TO 4 were exercisable to over 98 per cent and